From 1 September 2025, Prevenar 20 will replace Prevenar 13

Pneumovax 23 on the childhood and adolescent National Immunisation Program (NIP) schedule.

Routine doses are scheduled at 6 weeks, 4 months and 12 months of age, with an additional dose given for higher risk children at 6 months of age or at diagnosis of the at-risk condition. There is no need to recall a person for ‘catch-up’ if they have already completed their full course of pneumococcal vaccination.

Prevenar 20 is a conjugated vaccine that protects against the bacteria 肺炎链球菌. In addition to the protection against the 13 serotypes covered in Prevenar 13, Prevenar 20 offers protection against serotypes 8, 10A, 11A, 12F, 15B, 22F, 33F.

There are no changes to the adult schedule at this time.

Read more on the program changes via the NIP Fact sheet
Read more about pneumococcal at MVEC:肺炎球菌

For further information and the opportunity to ask questions, please save the date for MVEC’s upcoming webinar CVU mini: Pneumococcal update. (Recording now available exclusively for Education Portal members.)

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。

分享这个